Hematologic Toxicities in Colorectal Cancer Patients who Received FOLFOX4

Hematologic Toxicities in Colorectal Cancer Patients who Received FOLFOX4

Background: Over the past decade, survival from advanced colorectal cancer is increasing. Therefore patients have more exposure to chemotherapy and related toxicities. This study determines how hematologic toxicity patterns affect therapy and care. Methods: From April 2010 to March 2013, we enro...

Full description

Bibliographic Details
Main Authors:	Mehdi Dehghani, Nematollah Hafezi, Reza Vojdani, Mani Ramzi, Mojtaba Karimi, Habib Nourani, Maryam Zakerinia, Zahra Bahador
Format:	Article
Language:	English
Published:	Shiraz University of Medical Sciences 2015-07-01
Series:	Middle East Journal of Cancer
Subjects:	Colorectal cancer Chemotherapy FOLFOX4 Granulocyte colony stimulating factor Hematologic toxicities
Online Access:	http://mejc.sums.ac.ir/index.php/mejc/article/view/237/217

Similar Items

Clinical Significance of MMP7 Levels in Colorectal Cancer Patients Receiving FOLFOX4 Chemotherapy Treatment
by: Zhou Y, et al.
Published: (2023-06-01)

KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer
by: Yanhong Deng, et al.
Published: (2015-08-01)

Retrospective analysis on the clinical efficacy of bevacizumab combined with FOLFOX4 in the first line treatment of metastatic colorectal cancer
by: Eun Mi Lee, et al.
Published: (2017-12-01)

5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice
by: Takuo Yamai, et al.
Published: (2022-04-01)

A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer
by: Keisuke Okuno, et al.
Published: (2023-01-01)

Dynamic impact of inﬂammation-based indices in colorectal cancer patients receiving FOLFOX-based chemotherapy
by: Tao Y, et al.
Published: (2019-04-01)

Pulmonary Fibrosis Secondary to FOLFOX Chemotherapy: A Case Report
by: Wai Cheong Soon, et al.
Published: (2014-09-01)

Another treatment option for locally advanced hepatocellular carcinoma: Interventional arterial infusion of FOLFOX chemotherapy from the FOHAIC-1 study
by: Lyu Ning, et al.
Published: (2022-01-01)

The efficacy and safety of FOLFOX therapy for advanced esophageal squamous cell carcinoma
by: Kazuhiro Shiraishi, et al.
Published: (2025-03-01)

Clinical Significance of has_circ_0055625 in Colon Cancer Patients Undergoing FOLFOX Chemotherapy Treatment
by: Liu X, et al.
Published: (2021-01-01)

Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer
by: Bai L, et al.
Published: (2019-12-01)

Cetuximab plus FOLFOX for Patients with Metastatic Colorectal Cancer with Poor Performance Status and/or Severe Tumor-Related Complications
by: Kohei Shitara, et al.
Published: (2010-07-01)

Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer
by: Ren Hui, et al.
Published: (2011-09-01)

Efficacy and Safety of mFOLFOX-6 in Advanced Gastric Cancer: A Prospective Observational Study
by: Amrith B. Patel, et al.

Desulfovibrio desulfuricans and its derived metabolites confer resistance to FOLFOX through METTL3Research in context
by: Guifang Li, et al.
Published: (2024-04-01)

Quality of life in non-metastasic colorectal cancer patients in FOLFOX or XELOX therapy
by: Julia Sánchez-Gundín, et al.
Published: (2019-03-01)

Identification of LncRNAs Associated With FOLFOX Chemoresistance in mCRC and Construction of a Predictive Model
by: Yiyi Zhang, et al.
Published: (2021-01-01)

mFOLFOX6 Chemotherapy after Resection of Anal Canal Mucinous Adenocarcinoma
by: Mototsugu Matsunaga, et al.
Published: (2016-04-01)

Global impact of KRAS mutations patterns in FOLFOX treated metastatic colorectal cancer
by: David eMolinas Zocche, et al.
Published: (2015-03-01)

Protective effect of miR‐18a in resected liver metastases of colorectal cancer and FOLFOX treatment
by: Clemens Franz, et al.
Published: (2023-12-01)

FOLFOX treatment response prediction in metastatic or recurrent colorectal cancer patients via machine learning algorithms
by: Wei Lu, et al.
Published: (2020-02-01)

Retrospective Analysis of the Safety of FOLFOX Compared to CAPOX for Adjuvant Treatment of Stage III Colorectal Cancer in Newfoundland Patients
by: Joshua N. McShane, et al.
Published: (2022-09-01)

LABS score– a prognostic tool for FOLFOX4-treated advanced hepatocellular carcinoma and real-world efficacy: a single-center retrospective study
by: Jirapat Wonglhow, et al.
Published: (2024-03-01)

FOLFOX activity in a rare case of metastatic colonic adenocarcinoma of the tongue: a case report
by: Clizia Zichi, et al.
Published: (2018-04-01)

Single-cell analysis reveals cellular reprogramming in advanced colon cancer following FOLFOX-bevacizumab treatment
by: Meiling Yang, et al.
Published: (2023-07-01)

Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial
by: Jii Bum Lee, et al.
Published: (2020-04-01)

Sustained Improvement in a Metastatic Colon Cancer Patient with FOLFIRI-Aflibercept after FOLFOX Failure
by: Shyam Aggarwal
Published: (2015-11-01)

Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301)
by: Keisuke Miwa, et al.
Published: (2021-01-01)

Akkermansia Muciniphila Potentiates the Antitumor Efficacy of FOLFOX in Colon Cancer
by: Xiaoying Hou, et al.
Published: (2021-09-01)

A Case of Advanced Gastric Cancer with Para-Aortic Lymph Node Metastasis Treated with Preoperative FOLFOX Chemotherapy Followed by Radical Subtotal Gastrectomy and D2 Lymph Node Dissection
by: Byoung Jo Suh
Published: (2017-02-01)

Predictive factor for excessive myelosuppression in patients receiving chemotherapy for breast cancer
by: Jung Suk Lee, et al.
Published: (2016-06-01)

Beneficial Treatment Management with Trifluridine/Tipiracil in a Patient with Metastatic Colorectal Cancer and Pronounced Hematological Event History during Previous Treatments
by: Volker Kaechele, et al.
Published: (2018-01-01)

A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab
by: Erin D. Powell, et al.
Published: (2009-07-01)

Metastatic Urothelial Carcinoma with Glandular Differentiation That Confirmed the Response by Autopsy Specimen to Second-Line mFOLFOX6 (Fluorouracil, Oxaliplatin, and Leucovorin) plus Bevacizumab Chemotherapy
by: Taku Naiki, et al.
Published: (2017-11-01)

Cost-Effectiveness Analysis of Hepatic Arterial Infusion of FOLFOX Combined Sorafenib for Advanced Hepatocellular Carcinoma With Portal Vein Invasion
by: Meiyue Li, et al.
Published: (2021-03-01)

Prognosis and treatment of FOLFOX therapy related interstitial pneumonia: a plea for multimodal immune modulating therapy in the respiratory insufficient patient
by: Annick De Weerdt, et al.
Published: (2017-08-01)

FBXW4 Acts as a Protector of FOLFOX-Based Chemotherapy in Metastatic Colorectal Cancer Identified by Co-Expression Network Analysis
by: Yiyi Zhang, et al.
Published: (2020-03-01)

miRNAs and lncRNAs as Predictive Biomarkers of Response to FOLFOX Therapy in Colorectal Cancer
by: Kha Wai Hon, et al.
Published: (2018-08-01)

Hematology and Plasma Chemistry Reference Values in Nursehound Shark (Scyliorhinus Stellaris) Maintained Under Human Care
by: Pablo Morón-Elorza, et al.
Published: (2022-07-01)

Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab
by: Mototsugu Matsunaga, et al.
Published: (2016-04-01)